FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

TAKEDA PHARMACEUTICAL CO LTD

 2. Date of Event Requiring Statement (MM/DD/YYYY)
10/28/2019 

 3. Issuer Name and Ticker or Trading Symbol

BiomX Inc. [PHGE]

(Last)        (First)        (Middle)

1-1, NIHONBASHI-HONCHO 2 CHOME, CHUO-KU

 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)

(Street)

TOKYO, M0 103-8668      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)

 

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 2470935 I See footnote (1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of 2,470,935 shares of Common Stock held by Takeda Ventures, Inc., a wholly-owned indirect subsidiary of Takeda Pharmaceutical Company Limited. Takeda Ventures, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (58.09%) and Takeda Pharmaceuticals International AG (41.91%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
TAKEDA PHARMACEUTICAL CO LTD
1-1, NIHONBASHI-HONCHO 2 CHOME
CHUO-KU
TOKYO, M0 103-8668
X

Takeda Ventures, Inc.
435 TASSO STREET, SUITE 300
PALO ALTO, CA 94301
X
Signatures
Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company Limited11/5/2019
**Signature of Reporting PersonDate

Michael Martin, President of Takeda Ventures, Inc.11/5/2019
**Signature of Reporting PersonDate
Chardan Healthcare Acqui... (AMEX:CHAC)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Chardan Healthcare Acqui... Charts.
Chardan Healthcare Acqui... (AMEX:CHAC)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Chardan Healthcare Acqui... Charts.